MHSPC
Clinical trials for MHSPC explained in plain language.
Never miss a new study
Get alerted when new MHSPC trials appear
Sign up with your email to follow new studies for MHSPC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to tame advanced prostate cancer with fewer side effects
Disease control Not yet recruitingThis study tests a combination of darolutamide, hormone therapy (ADT), and a lower dose of the chemotherapy drug docetaxel in men with metastatic hormone-sensitive prostate cancer (mHSPC). The goal is to see if this approach can keep PSA levels very low while reducing the harsh s…
Matched conditions: MHSPC
Phase: PHASE2 • Sponsor: Yonghong Li • Aim: Disease control
Last updated May 26, 2026 07:41 UTC
-
New combo therapy for advanced prostate cancer enters early testing
Disease control Not yet recruitingThis early-phase study tests a new drug called LC-K76 combined with standard hormone therapy in 40 men with metastatic hormone-sensitive prostate cancer. The main goal is to check safety and side effects, while also looking at how well it controls the cancer, such as lowering PSA…
Matched conditions: MHSPC
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 26, 2026 07:36 UTC
-
Can a simple blood test predict prostate cancer treatment success?
Knowledge-focused Not yet recruitingThis study looks at whether a test called minimal residual disease (MRD) can help predict how well treatment works in men with metastatic hormone-sensitive prostate cancer. Researchers will follow 50 newly diagnosed patients to see how different gene patterns affect treatment res…
Matched conditions: MHSPC
Sponsor: Anhui Medical University • Aim: Knowledge-focused
Last updated May 26, 2026 07:26 UTC